BRISTOL-MYERS SQUIBB COMPANY Inventory, Work in Process, Net of Reserves
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Inventory, Work in Process, Net of Reserves of $3.04 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Inventory › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryWorkInProcessNetOfReserves · last filed 2026-07-30
- 2026-06-30: Inventory, Work in Process, Net of Reserves $3.04B.
- 2026-03-31: Inventory, Work in Process, Net of Reserves $3.10B.
- 2025-12-31: Inventory, Work in Process, Net of Reserves $3.16B.
- 2025-09-30: Inventory, Work in Process, Net of Reserves $3.06B.
| Period end | Inventory, Work in Process, Net of Reserves | Inventory, Work in Process, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $3.04B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $3.10B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $3.16B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $3.06B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $2.92B 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $2.77B 10-Q · filed 2025-04-24 | |
| 2024-12-31 | $2.55B 10-K · filed 2026-02-11 | |
| 2024-09-30 | $3.01B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $2.81B 10-Q · filed 2024-07-26 | |
| 2024-03-31 | $2.50B 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $2.43B 10-K · filed 2025-02-12 | |
| 2023-09-30 | $2.29B 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $2.04B 10-Q · filed 2023-07-27 | |
| 2023-03-31 | $1.94B 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $1.85B 10-K · filed 2024-02-13 | |
| 2022-09-30 | $1.87B 10-Q · filed 2022-10-26 | |
| 2022-06-30 | $1.91B 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $2.05B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $2.11B 10-K · filed 2023-02-14 | |
| 2021-09-30 | $1.78B 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $1.85B 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $1.94B 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $2.02B 10-K · filed 2022-02-09 | |
| 2020-09-30 | $2.07B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.86B 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $2.65B 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $3.27B 10-K · filed 2021-02-10 | |
| 2019-09-30 | $1.12B 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $916.00M 10-Q · filed 2019-07-25 | |
| 2019-03-31 | $934.00M 10-Q · filed 2019-04-25 | |
| 2018-12-31 | $1.15B 10-K · filed 2020-02-24 | $1.03B 10-K · filed 2019-02-25 |
| 2017-12-31 | $931.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |